PEG-hemoglobin data

ENZN completed a Phase I study of its polyethylene glycol-conjugated bovine hemoglobin in 28 volunteers, which indicated the product is safe and generally well-tolerated.

Subjects were injected with the product once, and monitored for five days, with weekly follow-up exams for three weeks. At 1.5 units, no organ toxicity and good hemodynamics were observed, the Piscataway, N.J., company said. Some gastrointestinal upset was noted, but the company expects to use only one unit for treatment, which it said should lessen those effects. ENZN plans to start a Phase I/II multidose trial in cancer patients this year. ...